
Advaita Corporation Profile last edited on: 12/23/2020
CAGE: 394T1
UEI: Q81XNNYPK5H3
Business Identifier: Next generation bioinformatic tools Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
3250 Plymouth Road Suite 303
Ann Arbor, MI 48105
Ann Arbor, MI 48105
(734) 922-0110 |
info@advaitacorporation.com |
www.advaitacorporation.com |
Location: Single
Congr. District: 06
County: Wayne
Congr. District: 06
County: Wayne
Public Profile
Software tools developed and offered by Advaita Bioinformatics are designed to assist help principal investigators, core facilities, and enterprise bioinformatics teams to analyze gene expression data (e.g. RNA-Seq or microarray) and variant data (e.g. DNA-Seq), to find biomarkers, identify impacted pathways, and pinpoint putative mechanisms. Currently, this process can be slow, frustratingly unreliable, expensive, and often requires multiple disjointed tools, which then provide irrelevant or incorrect results. Targeted at the needs of the research and pharmaceutical industries, the company offers Pathway-Guide, a gene-expression analysis tool that helps biologists and drug researchers interpret and make sense of the gigabytes of information produced as a result of their gene-expression experiments;; iVariantGuide and iBioGuide - described as Google for Scientists. Advaita Corporation also offers consulting services to include analyzing and interpreting pathways, building biological models, identifying and prioritizing biomarkers, interpreting expression data, creating report summaries and graphics, and data interpretation training.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 2 | NIH | $1,774,808 | |
Project Title: A web-based platform for robust single-cell analysis, bulk data deconvolution and system-level analysis | ||||
2023 | 2 | NSF | $1,082,298 | |
Project Title: A Multi-Omics Data Integration Approach for Precision Medicine and Improved Clinical Trial Success | ||||
2020 | 1 | NSF | $255,993 | |
Project Title: A knowledge base and drug repurposing platform for COVID-19 | ||||
2016 | 2 | NIH | $1,908,923 | |
Project Title: Pathway Analysis Tools for Personalized Medicine and Drug Repositioning | ||||
2013 | 2 | NIH | $2,357,483 | |
Project Title: A Novel Method for Signaling Pathway Analysis |
Key People / Management
Sorin Draghici -- Founder
John Richard Hartman
Iosef
Andrew Olson -- VP Business Development
Calin Voichita
Cordelia Ziraldo
John Richard Hartman
Iosef
Andrew Olson -- VP Business Development
Calin Voichita
Cordelia Ziraldo